Abstract:BACKGROUND:Diabetes mellitus is characterized by loss or dysfunction of insulin-producing β-cells in the pancreas, resulting in failure of blood glucose regulation and devastating secondary complications. Thus, β-cells are currently the prime target for cell-replacement and regenerative therapy. Triggering endogenous repair is a promising strategy to restore β-cell mass and normoglycemia in diabetic patients. Potential strategies include targeting specific β-cell subpopulations to increase proliferation or maturation. Alternatively, transdifferentiation of pancreatic islet cells (e.g. α- or δ-cells), extra-islet cells (acinar and ductal cells), hepatocytes, or intestinal cells into insulin-producing cells might improve glycemic control. To this end, it is crucial to systematically characterize and unravel the transcriptional program of all pancreatic cell types at the molecular level in homeostasis and disease. Furthermore, it is necessary to better determine the underlying mechanisms of β-cell maturation, maintenance, and dysfunction in diabetes, to identify and molecularly profile endocrine subpopulations with regenerative potential, and to translate the findings from mice to man. Recent approaches in single-cell biology started to illuminate heterogeneity and plasticity in the pancreas that might be targeted for β-cell regeneration in diabetic patients.SCOPE OF REVIEW:This review discusses recent literature on single-cell analysis including single-cell RNA sequencing, single-cell mass cytometry, and flow cytometry of pancreatic cell types in the context of mechanisms of endogenous β-cell regeneration. We discuss new findings on the regulation of postnatal β-cell proliferation and maturation. We highlight how single-cell analysis recapitulates described principles of functional β-cell heterogeneity in animal models and adds new knowledge on the extent of β-cell heterogeneity in humans as well as its role in homeostasis and disease. Furthermore, we summarize the findings on cell subpopulations with regenerative potential that might enable the formation of new β-cells in diseased state. Finally, we review new data on the transcriptional program and function of rare pancreatic cell types and their implication in diabetes.MAJOR CONCLUSION:Novel, single-cell technologies offer high molecular resolution of cellular heterogeneity within the pancreas and provide information on processes and factors that govern β-cell homeostasis, proliferation, and maturation. Eventually, these technologies might lead to the characterization of cells with regenerative potential and unravel disease-associated changes in gene expression to identify cellular and molecular targets for therapy.

Rejuvenation Of Beta Cells By Epigenetic Editing

Rejuvenation of β cells by epigenetic editing.

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Systematic Single-Cell Analysis Provides New Insights into Heterogeneity and Plasticity of the Pancreas.

Pancreatic Beta Cell Regeneration Induced By Clinical And Preclinical Agents

Chemical Strategies for Pancreatic Β Cell Differentiation, Reprogramming, and Regeneration

Targeted Pharmacological Therapy Restores Beta-Cell Function For Diabetes Remission

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

P21cip-overexpression in the Mouse Beta Cells Leads to the Improved Recovery from Streptozotocin-Induced Diabetes.

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

From islet transplantation to beta-cell regeneration: an update on beta-cell-based therapeutic approaches in type 1 diabetes

Endogenous Pancreatic Beta Cell Regeneration: A Potential Strategy For The Recovery Of Beta Cell Deficiency In Diabetes

Lineage Reprogramming: A Promising Road for Pancreatic β Cell Regeneration.

Advances in Drug Discovery for Human Beta Cell Regeneration

Update on the transdifferentiation of pancreatic cells into functional beta cells for treating diabetes

Generating Insulin-Producing Cells for Diabetic Therapy: Existing Strategies and New Development

Pancreatic -cell failure, clinical implications, and therapeutic strategies in type 2 diabetes

EZH2 inhibitors promote β-like cell regeneration in young and adult type 1 diabetes donors

Advancing diabetes management: Exploring pancreatic beta-cell restoration's potential and challenges

Various Chemical Strategies & Mediators that Improve Beta-Cell Function Through Regeneration and Reprogramming